Key Highlights

  • Notes carry an 8% annual interest rate, escalating to 15% upon default, and include warrants exercisable at the same $5.40 price.
  • Funding for the second tranche hinges on either a 150% increase in ReWalk unit sales or LFWD stock reaching $13.80 per share.
  • Investors face a 4.99% beneficial ownership cap and a 19.99% exchange cap on share issuance.

Lifeward Ltd. (NASDAQ: LFWD) has finalized a structured financing deal, issuing convertible notes and warrants to accredited investors. The transaction, led by Oramed Pharmaceuticals Inc. As collateral agent, provides immediate capital while tying future funding to performance milestones.

Financing Structure

The company secured $5.58 million in initial notes, convertible at $5.40 per share, alongside warrants exercisable at the same price. A second $5.58 million tranche remains conditional, requiring either a 150% surge in ReWalk unit sales or LFWD shares trading at or above $13.80 for ten consecutive days.

Interest and Redemption Terms

Notes accrue interest at 8% annually, payable semi-annually starting December 31, 2026. In default scenarios, the rate jumps to 15%. Investors may convert principal and accrued interest into ordinary shares at any time, subject to ownership limits.

Warrant Details

Warrants cover up to 100% of the shares issuable under the notes, with a five-year term and cashless exercise option. Both notes and warrants include standard anti-dilution adjustments for corporate actions like stock splits.

Ownership Restrictions

Investors cannot exceed a 4.99% beneficial ownership stake without a 61-day notice period. The total shares issuable under the notes and warrants are capped at 19.99% of outstanding shares unless shareholder approval is obtained.

Registration Requirements

Lifeward must file a registration statement for the underlying shares within 30 days of closing, aiming for SEC effectiveness within 45 days, or 75 days if the SEC initiates a review.

Collateral and Compliance

Oramed serves as collateral agent for the secured notes. The offering was conducted under Regulation D, exempt from SEC registration, and restricted to accredited investors.

Milestone Triggers

The second tranche’s release depends on either a 150% increase in ReWalk sales or LFWD’s stock price sustaining $13.80 for ten trading days. Both conditions are tied to the company’s operational and market performance.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.